{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:32:38Z","timestamp":1791203558932,"version":"4.2.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00262-020-02637-1","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T16:05:57Z","timestamp":1592582757000},"page":"2513-2522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2943-0648","authenticated-orcid":false,"given":"A.","family":"Simonaggio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Elaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Borchiellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Thouvenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tartour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. A.","family":"Vano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"issue":"1","key":"2637_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2637_CR2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/iju.12187","volume":"20","author":"H Abe","year":"2013","unstructured":"Abe H, Kamai T (2013) Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol Off J Jpn Urol Assoc 20(10):944\u2013955. https:\/\/doi.org\/10.1111\/iju.12187","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"issue":"17","key":"2637_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab vs docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"issue":"2","key":"2637_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab vs docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"issue":"19","key":"2637_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab vs everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"19","key":"2637_CR6","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab vs chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"issue":"34","key":"2637_CR7","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","volume":"35","author":"HJ Hammers","year":"2017","unstructured":"Hammers HJ, Plimack ER, Infante JR et al (2017) Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol Off J Am Soc Clin Oncol 35(34):3851\u20133858. https:\/\/doi.org\/10.1200\/JCO.2016.72.1985","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2637_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu T-E, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1801946","journal-title":"N Engl J Med"},{"issue":"54","key":"2637_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"2016","author":"JM Michot","year":"1990","unstructured":"Michot JM, Bigenwald C, Champiat S et al (1990) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer Oxf Engl 2016(54):139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"8","key":"2637_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473. https:\/\/doi.org\/10.1038\/nrclinonc.2016.58","journal-title":"Nat Rev Clin Oncol"},{"key":"2637_CR11","unstructured":"Hallmarks of Cancer: The next generation: cell. https:\/\/www.cell.com\/cell\/fulltext\/S0092-8674(11)00127-9?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867411001279%3Fshowall%3Dtrue. Published September 3, 2017. Accessed 3 Sep 2017."},{"issue":"6","key":"2637_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883\u2013899. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025","journal-title":"Cell"},{"issue":"2","key":"2637_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.coi.2007.02.001","volume":"19","author":"JD Bui","year":"2007","unstructured":"Bui JD, Schreiber RD (2007) Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19(2):203\u2013208. https:\/\/doi.org\/10.1016\/j.coi.2007.02.001","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"2637_CR14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.imbio.2013.06.003","volume":"218","author":"MR Galdiero","year":"2013","unstructured":"Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218(11):1402\u20131410. https:\/\/doi.org\/10.1016\/j.imbio.2013.06.003","journal-title":"Immunobiology"},{"issue":"6","key":"2637_CR15","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, Eruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI J Natl Cancer Inst 106(6):dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"2637_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.clgc.2016.04.008","volume":"14","author":"M Marchioni","year":"2016","unstructured":"Marchioni M, Primiceri G, Ingrosso M et al (2016) The clinical use of the neutrophil to lymphocyte ratio (NLR) in urothelial cancer: a systematic review. Clin Genitourin Cancer 14(6):473\u2013484. https:\/\/doi.org\/10.1016\/j.clgc.2016.04.008","journal-title":"Clin Genitourin Cancer"},{"key":"2637_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-016-1593-y","author":"V Bar-Ad","year":"2016","unstructured":"Bar-Ad V, Palmer J, Li L et al (2016) Neutrophil to lymphocyte ratio associated with prognosis of lung cancer. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. https:\/\/doi.org\/10.1007\/s12094-016-1593-y","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"2637_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195042","author":"Y-A Vano","year":"2018","unstructured":"Vano Y-A, Oudard S, By M-A et al (2018) Optimal cut-off for neutrophil-to-lymphocyte ratio: fact or fantasy? A prospective cohort study in metastatic cancer patients. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0195042","journal-title":"PLoS ONE"},{"issue":"1","key":"2637_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","volume":"6","author":"A-KA Lalani","year":"2018","unstructured":"Lalani A-KA, Xie W, Martini DJ et al (2018) Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer 6(1):5. https:\/\/doi.org\/10.1186\/s40425-018-0315-0","journal-title":"J Immunother Cancer"},{"key":"2637_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197743","author":"M Khunger","year":"2018","unstructured":"Khunger M, Patil PD, Khunger A et al (2018) Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0197743","journal-title":"PLoS ONE"},{"issue":"89","key":"2637_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2017.11.012","volume":"2018","author":"M Ameratunga","year":"1990","unstructured":"Ameratunga M, Ch\u00e9nard-Poirier M, Moreno Candilejo I et al (1990) Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1\/PD-L1 inhibitors. Eur J Cancer Oxf Engl 2018(89):56\u201363. https:\/\/doi.org\/10.1016\/j.ejca.2017.11.012","journal-title":"Eur J Cancer Oxf Engl"},{"key":"2637_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","volume":"106","author":"SJ Bagley","year":"2017","unstructured":"Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer Amst Neth 106:1\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2017.01.013","journal-title":"Lung Cancer Amst Neth"},{"key":"2637_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193018","author":"T Kiriu","year":"2018","unstructured":"Kiriu T, Yamamoto M, Nagano T et al (2018) The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0193018","journal-title":"PLoS ONE"},{"key":"2637_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","volume":"111","author":"S Diem","year":"2017","unstructured":"Diem S, Schmid S, Krapf M et al (2017) Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer Amst Neth 111:176\u2013181. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.024","journal-title":"Lung Cancer Amst Neth"},{"key":"2637_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-1250-2","author":"A Nakaya","year":"2018","unstructured":"Nakaya A, Kurata T, Yoshioka H et al (February 2018) Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-018-1250-2","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"2637_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/cam4.1234","volume":"7","author":"T Shiroyama","year":"2018","unstructured":"Shiroyama T, Suzuki H, Tamiya M et al (2018) Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med 7(1):13\u201320. https:\/\/doi.org\/10.1002\/cam4.1234","journal-title":"Cancer Med"},{"issue":"1","key":"2637_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L et al (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):218. https:\/\/doi.org\/10.1186\/s13059-016-1070-5","journal-title":"Genome Biol"},{"issue":"25","key":"2637_CR28","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 377(25):2500\u20132501. https:\/\/doi.org\/10.1056\/NEJMc1713444","journal-title":"N Engl J Med"},{"issue":"3","key":"2637_CR29","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143\u2013e152. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"2637_CR30","unstructured":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.\u2014PubMed\u2014NCBI. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=T-cell+invigoration+to+tumour+burden+ratio+associated+with+anti-+PD-1+response. Accessed 22 June 2019."},{"issue":"31","key":"2637_CR31","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 33(31):3541\u20133543. https:\/\/doi.org\/10.1200\/JCO.2015.61.6870","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"2637_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","volume":"72","author":"B Escudier","year":"2017","unstructured":"Escudier B, Motzer RJ, Sharma P et al (2017) Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol 72(3):368\u2013376. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.037","journal-title":"Eur Urol"},{"issue":"7","key":"2637_CR33","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","volume":"30","author":"F Colotta","year":"2009","unstructured":"Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073\u20131081. https:\/\/doi.org\/10.1093\/carcin\/bgp127","journal-title":"Carcinogenesis"},{"issue":"1","key":"2637_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms14381","volume":"8","author":"J Kargl","year":"2017","unstructured":"Kargl J, Busch SE, Yang GHY et al (2017) Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun 8(1):1\u201311. https:\/\/doi.org\/10.1038\/ncomms14381","journal-title":"Nat Commun"},{"issue":"6","key":"2637_CR35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/crj.12417","volume":"11","author":"N Dirican","year":"2017","unstructured":"Dirican N, Karakaya YA, Gunes S, Daloglu FT, Dirican A (2017) Association of intra-tumoral tumour-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio is an independent prognostic factor in non-small cell lung cancer. Clin Respir J 11(6):789\u2013796. https:\/\/doi.org\/10.1111\/crj.12417","journal-title":"Clin Respir J"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02637-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02637-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02637-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T23:27:57Z","timestamp":1624058877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02637-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2637"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02637-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YV, SO, CT and PB: consulting fees from BMS, MSD, Pfizer, Novartis, Ipsen, Roche, Astellas, Sanofi, Janssen. DB: funding to institution for clinical research, advisory role or travel accommodation: Bristol-Meyers Squibb, Pfizer, Roche, Ipsen, MSD, Astra-Zeneca. No potential conflicts of interest were disclosed by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local institutional review board and was conducted with Good Clinical Practice Guidelines and the Declaration of Helsinki. All patients gave their oral consent. CNIL declaration No 2215794 v 0","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication has been obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}